Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

Rhea-AI Summary

Dassault Systèmes (OTC:DASTY) announced that its Medidata brand has extended a 10-plus-year collaboration with Sanofi to support clinical research and speed therapy development. Sanofi will use Medidata Patient, Data, and Study Experiences, including AI-embedded, platform-based solutions and decentralized trial capabilities, with Medidata supplying consulting and end-to-end operational support. The extension aims to unify clinical workflows, reduce silos, and shorten delays to accelerate new therapies and improve patient journeys.

Positive

• 10-plus-year collaboration extension with Sanofi
• Sanofi to adopt Medidata Patient, Data, and Study Experiences
• Inclusion of AI-embedded platform solutions across clinical workflows
• Medidata to provide consulting and end-to-end operational support
• Sanofi will use Medidata decentralized clinical trial capabilities

Negative

• None.

Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey 

Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care

New York – Oct. 23, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration with Sanofi in clinical research. As part of this extension Sanofi will use the Medidata Patient, Data, and Study Experiences, building on the organizations’ vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.

The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge can help advance studies, amplifying the development of therapies with greater precision and impact.

Sanofi will employ Medidata’s expertise and capabilities in decentralized clinical trials as part of the extension of this agreement. Medidata will provide consulting and end-to-end operational support.

“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through this agreement, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the clinical development process.”

To learn more about the Medidata Experiences, please visit here.

About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast, from Dreamers to Disruptors, and follow us at @Medidata.

About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com.

Contact:

Medidata PR

Medidata.PR@3ds.com

Analyst Relations

medidata.AR@3ds.com

Attachment

• Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

FAQ

What did Dassault Systèmes announce about Medidata and Sanofi on October 28, 2025?

Medidata extended a 10-plus-year collaboration with Sanofi for clinical research using Medidata Patient, Data, and Study Experiences.

How will the Medidata collaboration affect Sanofi's clinical trials (DASTY)?

Sanofi will use Medidata's AI-embedded platform and decentralized trial tools to unify workflows and aim to reduce delays and costs.

What specific Medidata solutions will Sanofi use under the DASTY collaboration extension?

Sanofi will use Medidata Patient, Data, and Study Experiences plus decentralized clinical trial capabilities and operational consulting.

Does the announcement include financial terms or revenue guidance for DASTY?

No; the announcement does not disclose any financial terms, contract value, or revenue guidance.

What operational support will Medidata provide Sanofi under the extended agreement (DASTY)?

Medidata will provide consulting and end-to-end operational support to help execute and accelerate clinical development.